APT-CEST post Gadolinium: Should it be avoided? Comparison of pre- 
post-Gadolinium CEST on glioma at 3T

Torrealdea, F; Hearle, J; Evans, V; Zaiss, M; Carvalho, A; Shankar, A; Hyare, H; Atkinson, D; Golay, X; Barnes, A; Rega, M

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Poster

APT-CEST post Gadolinium: Should it be avoided? Comparison of pre- post-Gadolinium CEST on glioma at 3T

MPS-Authors

/persons/resource/persons214560

Zaiss, M
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

Link
(Abstract)

https://www.ismrm.org/18/Electronic_Posters.pdf
(Abstract)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Torrealdea, F., Hearle, J., Evans, V., Zaiss, M., Carvalho, A., Shankar, A., et al. (2018). APT-CEST post Gadolinium: Should it be avoided? Comparison of pre- post-Gadolinium CEST on glioma at 3T. Poster presented at Joint Annual Meeting ISMRM-ESMRMB 2018, Paris, France.

Cite as: https://hdl.handle.net/21.11116/0000-0001-7D75-0

Abstract

This study compares APT-CEST between pre- and post-gadolinium in patients with gliomas at 3T, and evaluates the feasibility of performing CEST after administration of T1 contrast. The results of the study demonstrate that Gd administration does not significantly affect the quality of the APT-CEST image, encouraging the acquisition of CEST data, even after the administration of T1 contrast agents.